Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
The Consortium for Clinical Research and Innovation (CRIS) will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 to check if you are unsure if something is a scam or visit the ScamShield (opens in new tab) website for more information.

Consortium for Clinical Research and Innovation, Singapore (CRIS)

Jul: Accelerating Clinical Innovations into Market

Catch up on July's CRIS Connect Webinar, where experts shared how NHIC helps bring clinical innovations to market and improve patient outcomes.

Last updated on 8 September 2026

Recap key insights from July's CRIS Connect Webinar:

The webinar spotlighted the pivotal role of the National Health Innovation Centre Singapore (NHIC) in advancing the local healthtech ecosystem by identifying, funding, and commercialising clinical innovations from public health institutions.

Four slides on healthcare innovation, with titles on NHIC, clinical innovations, cryocompression system, and blurred faces.

With its dual mandate of economic growth and healthcare impact, NHIC provides project guidance, consultancy, and strategic partnerships spanning co-development, co-funding, test-bedding, and global market access. These efforts not only accelerate translation from bench to bedside but also foster meaningful international collaborations that expand opportunities for Singapore’s clinical community.

A prime example would be the Paxman Limb Cryocompression System (PLCS), a local innovation to prevent chemotherapy-induced peripheral neuropathy. Combining limb cooling with cyclic compression, the device enhances patient safety and tolerability compared to traditional frozen gloves. Spanning multiple sites in Singapore, the trial saw 76.5% of patients completing all planned treatment with cryocompression, while the drop-out rate was only 9.7% due to cold intolerance. In all, 67% of patients completed the treatment without dose reduction.

PLCS’ journey from proof-of-concept to global clinical trials highlights how multidisciplinary collaboration, engaging user feedback and NHIC’s support can fast-track promising technologies into impactful healthcare solutions to deliver better patient outcomes.